Anti-HER2 therapy for HER2-positive metastatic breast cancer: regimens and treatment outcomes

被引：0
|
作者：
Watanabe, Kenichi [1 ]
Hagio, Kanako [1 ]
Baba, Motoi [1 ]
Ikarashi, Mayuko [1 ]
Sato, Masako [1 ]
Tomioka, Nobumoto [1 ]
Takahashi, Masato [1 ]
机构：
[1] Hokkaido Canc Ctr, Dept Breast Surg, Sapporo, Hokkaido, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-5-67
引用
收藏
页码：143 / 143
页数：1
相关论文
共 50 条
  • [1] Utilization of anti-HER2 regimens among HER2-positive metastatic breast cancer patients.
    Mehta, Sandhya
    Song, Jinlin
    Pavilack, Melissa
    Xie, Jipan
    Nie, Xiaoyu
    Vembusubramanian, Mohini
    Kwong, Jackie
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
  • [2] Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy
    Susanna Nguy
    S. Peter Wu
    Cheongeun Oh
    Naamit K. Gerber
    Breast Cancer Research and Treatment, 2021, 187 : 815 - 830
  • [3] Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy
    Nguy, Susanna
    Wu, S. Peter
    Oh, Cheongeun
    Gerber, Naamit K.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (03) : 815 - 830
  • [4] Margetuximab Anti-HER2 monoclonal antibody Treatment of metastatic HER2-positive breast cancer Treatment of HER2-positive gastric or gastroeso-phageal junction cancer
    Hanna, K. S.
    DRUGS OF THE FUTURE, 2021, 46 (03) : 191 - 195
  • [5] The incidence and outcomes of brain metastases in HER2-positive metastatic breast cancer with the advent of modern anti-HER2 therapies
    Shachar, S. Strulov
    Deal, A. M.
    Vaz-Luis, I.
    Dees, E. C.
    Carey, L. A.
    Hassett, M. J.
    Garrett, A. L.
    Benbow, J. M.
    Hughes, M. E.
    Mounsey, L.
    Lin, N.
    Anders, C. K.
    CANCER RESEARCH, 2017, 77
  • [6] Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer
    Yu, Anthony F.
    Singh, Jasmeet C.
    Wang, Rui
    Liu, Jennifer E.
    Eaton, Anne
    Oeffinger, Kevin C.
    Steingart, Richard M.
    Hudis, Clifford A.
    Dang, Chau T.
    ONCOLOGIST, 2017, 22 (06): : 642 - 647
  • [7] Differential responses of HER2-positive breast cancer cells to anti-HER2 treatment.
    Yu, Rong
    Chiu, Kung Y.
    Shi, Lili
    Zhang, Peter
    Duan, Chun-Xiao
    Lu, Sunny
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens
    Azadeh Nasrazadani
    Juan Luis Gomez Marti
    Kate Lathrop
    Alvaro Restrepo
    Szu-Yun Leu
    Gajanan Bhat
    Adam Brufsky
    Breast Cancer Research and Treatment, 2024, 205 : 29 - 37
  • [9] Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens
    Nasrazadani, Azadeh
    Marti, Juan Luis Gomez
    Lathrop, Kate
    Restrepo, Alvaro
    Leu, Szu-Yun
    Bhat, Gajanan
    Brufsky, Adam
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 205 (01) : 29 - 37
  • [10] Peripheral blood monocyte count prediction for anti-HER2 combination therapy: Outcomes in HER2-positive metastatic breast cancer patients.
    Radwi, Amer Naeem
    Albeladi, Reyadh Khalid
    Alzahrani, Shahrazad Abdulsalam
    Alahmadi, Raghad Abdulrahman
    Aljohani, Haneen Abdulrahman
    Ahmed, Dalia Ismaiel
    CANCER RESEARCH, 2021, 81 (13)
12345